Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.

The Journal of molecular diagnostics : JMD - 1 Jan 2011

Su Zengliu, Dias-Santagata Dora, Duke Markeesa, Hutchinson Katherine, Lin Ya-Lun, Borger Darrell R, Chung Christine H, Massion Pierre P, Vnencak-Jones Cindy L, Iafrate A John, Pao William

Abstract excerpt

The identification of somatically acquired tumor mutations is increasingly important in the clinical management of cancer because the sensitivity of targeted drugs is related to the genetic makeup of individual tumors. Thus, mutational profiles of tumors can help prioritize anticancer therapy. We report herein the development and validation of two multiplexed assays designed to detect in DNA from FFPE tissue more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Genetic Testing

Share to High-Throughput Nucleotide Sequencing

Share to Lung Neoplasms

Share to Mutation

Share to Reproducibility of Results

Source

Open in PubMed Open full text

Identifiers

PMID: 21227397
DOI: 10.1016/j.jmoldx.2010.11.010
PMCID: PMC3070558

Genes

EGFR
AKT1
BRAF
KRAS
NRAS
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.PMID 21227397Read ↗

Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.Semantic proximity Read ↗

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.Semantic proximity Read ↗

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.Semantic proximity Read ↗

Molecular profiling of non-small cell lung cancer.Semantic proximity Read ↗

Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.Semantic proximity Read ↗

The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC.Semantic proximity Read ↗

Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non-Small-Cell Lung Cancer: Results of a 2-Year Experience on 1343 Samples.Semantic proximity Read ↗

EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.Semantic proximity Read ↗

Development, testing and validation of a targeted NGS-panel for the detection of actionable mutations in lung cancer (NSCLC) using anchored multiplex PCR technology in a multicentric setting.Semantic proximity Read ↗

Routine Clinical Mutation Profiling of Non-Small Cell Lung Cancer Using Next-Generation Sequencing.Semantic proximity Read ↗

The introduction of systematic genomic testing for patients with non-small-cell lung cancer.Semantic proximity Read ↗

EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer: Current Treatment Landscape and Future Directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.